Jump-starting natural resilience reverses stress susceptibility: Novel therapy for treating depression

Science

Volumn 346, Issue 6209, 2014, Pages 554-554A

  Friedman, Allyson ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; POTASSIUM CHANNEL; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT;

BEHAVIORAL RESPONSE; BRAIN; ELECTRICAL METHOD; NEUROLOGY; RESEARCH PROGRAM; RODENT;

ANTIDEPRESSANT ACTIVITY; BRAIN; COPING BEHAVIOR; DEPRESSION; DOPAMINERGIC NERVE CELL; ELECTROPHYSIOLOGY; GENE TRANSFER; HYPERACTIVITY; NONHUMAN; OPTOGENETICS; PATHOGENESIS; PHENOTYPE; PLASTICITY; POTASSIUM CURRENT; REVIEW; STRESS; THERAPY EFFECT; UPREGULATION; VENTRAL TEGMENTUM; ANIMAL; ARTICLE; CHEMISTRY; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG DESIGN; DRUG EFFECT; HUMAN; MAJOR DEPRESSION; MENTAL STRESS; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

NEW YORK [NEW YORK (STT)]; NEW YORK [UNITED STATES]; UNITED STATES;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; DOPAMINE; DOPAMINE AGENTS; DOPAMINERGIC NEURONS; DRUG DESIGN; HUMANS; MICE; MOLECULAR TARGETED THERAPY; POTASSIUM CHANNELS; RESILIENCE, PSYCHOLOGICAL; STRESS, PSYCHOLOGICAL; VENTRAL TEGMENTAL AREA;

EID: 84908582617     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1260781     Document Type: Review

References (22)

1. WHO Initiative on Depression in Public Health (World Health Organization, 2009).
2. E. J. Nestler et al., Biol. Psychiatry 52, 503-528 (2002).
3. L. Culpepper, J. Clin. Psychiatry 71 (suppl.), 4-9 (2010).
4. E. J. Nestler et al., Neuron 34, 1 3-25 (2002).
5. O. Berton, E. J. Nestler, Nat. Rev. Neurosci. 7, 137-151 (2006).
6. Report of the National Advisory Mental Health Council's Workgroup. From Discovery to Cure (2010).
7. E. J. Nestler, W. A. Carlezon Jr., Biol. Psychiatry 59, 1151-1159 (2006).
8. H. Jick, J. A. Kaye, S. S. Jick, JAMA 292, 338-343 (2004).
9. R. W. Lam, J. Psychopharmacol. 24 (suppl.), 27-30 (2010).
10. S. M. Southwick, M. Vythilingam, D. S. Charney, Annu. Rev. Clin. Psychol. 1, 255-291 (2005).
11. D. S. Charney, H. K. Manji, Sci. STKE 2004, re5 (2004).
12. R. Yehuda, J. D. Flory, S. Southwick, D. S. Charney, Ann. N. Y. Acad. Sci. 1071, 379-396 (2006).
13. R. Yehuda, J. Clin. Psychiatry 65, 29-36 (2004).
14. P. A. Atkinson, C. R. Martin, J. Rankin, J. Psychiatr. Ment. Health Nurs. 16, 1 37-145 (2009).
15. M. Vythilingam et al., Psychiatry Res. 172, 75-77 (2009).
16. V. Krishnan et al., Cell 131, 391-404 (2007).
17. J.-L. Cao et al., J. Neurosci. 30, 16453-16458 (2010).
18. D. Chaudhury et al. Nature 493, 532-536 (2013).
19. J. J. Walsh et al., Nat. Neurosci. 17, 27-29 (2014).
20. H. Neuhoff, A. Neu, B. Liss, J. Roeper, J. Neurosci. 22, 1290-1302 (2002).
21. F. Arencibia-Albite, C. Paladini, J. T. Williams, C. A. Jiménez-Rivera, Neuroscience 149, 303-314 (2007).
22. A. K. Friedman et al., Science 344, 313-319 (2014).